Kelun-Biotech's Novel CLDN18.2 ADC SKB315 IND in Combination with Tagolizumab Receives NMPA Approval for the First-Line Treatment of Gastric/Gastro-oesophageal Junction Cancer

[
Kelun-Biotech's Novel CLDN18.2 ADC SKB315 IND in Combination with Tagolizumab Receives NMPA Approval for the First-Line Treatment of Gastric/Gastro-oesophageal Junction Cancer
[og_img]
https://www.investing.com/news/press-releases/kelunbiotechs-novel-cldn182-adc-skb315-ind-in-combination-with-tagolizumab-receives-nmpa-approval-for-the-firstline-treatment-of-gastricgastrooesophageal-junction-cancer-93CH-4092251


Investing.com